Sorafenib in the management of metastatic renal cell carcinoma

Current Oncology

Volumn 16, Issue S1, 2009, Pages S27-S32

  Guevremont, Catherine ^a   Jeldres, C ^a   Perrotte, P ^a   Karakiewicz, P I ^a  

^a NONE

Author keywords

metastatic renal cell carcinoma; Sorafenib; targeted therapy

Indexed keywords

EID: 75749119984     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v16i0.430     Document Type: Article

References (34)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24.
2. Escudier B, Eisen T, Stadler WM, et al. target Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;365:125–34. [Erratum in: N Engl J Med 2007;357:203]
3. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Global arcc Trial. N Engl J Med 2007;356:2271–81.
4. Escudier B, Pluzanska A, Koralewski P, et al. on behalf of the avoren Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase iii trial. Lancet 2007;370:2103–11.
5. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal-cell carcinoma: calgb 90206. J Clin Oncol 2008;33:5422–8.
6. Motzer RJ, Escudier B, Oudard S, et al. on behalf of the rec ord-1 Study Group. Efficacy of everolimus in advanced renalcell carcinoma: a double-blind, randomised, placebo-controlled phase iii trial. Lancet 2008;372:449–56.
7. National Comprehensive Cancer Network (nccn). Kidney Cancer. NCCN Clinical Practice Guidelines in Oncology. V.1.2009. Fort Washington, PA: nccn; 2008. [Available online at: www. nccn.org/professionals/physician_gls/PDF/kidney.pdf; cited March 3, 2009]
8. Ljungberg B, Hanbury DC, Kuczyk MA, et al. on behalf of the European Association of Urology (eau). Guidelines on Renal Cell Carcinoma. March 2007 update. Arnhem, Netherlands: eau; 2007. [Available online at: www.uroweb.org/fileadmin/ tx_eauguidelines/Renal%20Cell%20Carcinoma.pdf; cited March 3, 2009]
9. Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int 2009;103:572–7.
10. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/mek/ erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–109.
11. Awada A, Hendlisz A, Gil T, et al. Phase i safety and pharmacokinetics of BAY43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855–61.
12. Moore M, Hirte HW, Siu L, et al. Phase i study to determine the safety and pharmacokinetics of the novel Raf kinase and vegfr inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688–94.
13. Strumberg D, Richly H, Hilger RA, et al. Phase i clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965–72.
14. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472–80.
15. United States, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (ctep). Common Toxicity Criteria (CTC). ctc version 2.0. Bethesda, MD: ctep; 1999. [Available online at: ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf; cited February 20, 2009]
16. Ratain MJ, Eisen T, Stadler WM, et al. Phase ii placebocontrolled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505–12.
17. United States, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (ctep). Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0. Bethesda, MD: ctep; 2006. [Available online at: ctep. cancer.gov/protocolDevelopment/electronic_applications/docs/ ctcaev3.pdf; cited February 20, 2009]
18. Eisen T, Oudard S, Szczylik C, et al. on behalf of the target Study Group. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008;100:1454–63.
19. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase iii trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract 5023]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/ Abstracts?&vmview=abst_detail_view&confID=47&abstract ID=33741; cited March 3, 2009]
20. Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (arccs) expanded access trial in North America: safety and efficacy [abstract 5011]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/ Abstracts?&vmview=abst_detail_view&confID=47&abstract ID=34297; cited March 3, 2009]
21. Porta C, Bracarda S, Beck J, et al. Efficacy and safety of sorafenib in elderly pts: results from a large open-label, noncomparative phase iii study in European pts with advanced rcc (eu arccs) [abstract 596P]. Ann Oncol 2008;19(suppl 8):viii193. [Available online at: annonc.oxfordjournals.org/ cgi/reprint/19/suppl_8/viii187?maxtoshow=&HITS=10&hits =10&RESULTFORMAT=&fulltext=596P&searchid=1&FIR STINDEX=0&volume=19&issue=Supplement+8&resource type=HWCIT; cited March 12, 2009]
22. Beck J, Verzoni E, Negrier S, et al. on behalf of the eu-arccs study investigators. A large open-label, non-comparative, phase iii study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma [abstract 694]. Eur Urol Suppl 2008;7:244. [Available online at: download.journals.elsevierhealth.com/pdfs/journals/1569-9056/ PIIS1569905608606922.pdf; cited March 12, 2009]
23. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase ii trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;[Epub ahead of print].
24. Negrier S, Perol D, Ravaud A, et al. on behalf of The French Immunotherapy Intergroup. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007;110:2468–77.
25. Ryan CW, Goldman BH, Lara PN Jr, et al. on behalf of the Southwest Oncology Group. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase ii study of the Southwest Oncology Group. J Clin Oncol 2007;25:3296–301.
26. Tannir NM, Zurita AJ, Heymach JV, et al. A randomized phase ii trial of sorafenib versus sorafenib plus low-dose interferonalfa: clinical results and biomarker analysis [abstract 5093]. Proc Am Soc Clin Oncol 2008;26:272s. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/ Abstracts?&vmview=abst_detail_view&confID=55&abstract ID=34960; cited March 3, 2009]
27. Amato RJ, Harris P, Dalton M, et al. A phase ii trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (mrcc) [abstract 5026]. Proc Am Soc Clin Oncol 2007;25:241s. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/ Abstracts?&vmview=abst_detail_view&confID=47&abstract ID=35551; cited March 3, 2009]
28. Amato RJ, Jac J, Harris P, et al. A phase ii trial of intra-patient dose escalated-sorafenib in patients (pts) with metastatic renal cell cancer (mrcc) [abstract 5122]. Proc Am Soc Clin Oncol 2008;26:280s. [Available online at: www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35067; cited March 3, 2009]
29. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccrcc) refractory to prior sunitinib or bevacizumab [abstract 5123]. Proc Am Soc Clin Oncol 2008; 26:280s. [Available online at: www.asco.org/ASCO/Abstracts +%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_ view&confID=55&abstractID=35252; cited March 3, 2009]
30. Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients [abstract 5038]. Proc Am Soc Clin Oncol 2007; 25:244s. [Available online at: www.asco.org/ASCO/Abstracts +%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_ view&confID=47&abstractID=32197; cited March 3, 2009]
31. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115:61–7.
32. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81–6.
33. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26:127–31.
34. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917–30.